Patents Assigned to MEREO BIOPHARMA 4 LIMITED
  • METHODS INVOLVING NEUTROPHIL ELASTASE INHIBITOR ALVELESTAT FOR TREATING CORONAVIRUS INFECTION
    Publication number: 20230218596
    Abstract: The invention relates to treatments for coronavirus infections by administering a neutrophil elastase inhibitor, such as alvelestat.
    Type: Application
    Filed: March 16, 2021
    Publication date: July 13, 2023
    Applicants: MEREO BIOPHARMA 4 LIMITED, THE UAB RESEARCH FOUNDATION
    Inventors: Jacqueline PARKIN, James Michael WELLS, Mark DRANSFIELD
  • METHODS INVOLVING NEUTROPHIL ELASTASE INHIBITOR ALVELESTAT FOR TREATING RESPIRATORY DISEASE MEDIATED BY ALPHA-1 ANTITRYPSIN DEFICIENCY
    Publication number: 20230190723
    Abstract: The present invention discloses a dosage form and dosage regimen of 6-methyl-5-(1-methyl-1H-pyrazol-5-yl)-N-{[5-(methylsulfonyl)pyridin-2-yl]methyl}-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide (i.e. alvelestat) or salts thereof, and related methods of using the dosage form and dosage regimen.
    Type: Application
    Filed: March 16, 2021
    Publication date: June 22, 2023
    Applicant: MEREO BIOPHARMA 4 LIMITED
    Inventor: Jacqueline PARKIN
  • ALVELESTAT FOR USE IN THE TREATMENT OF GRAFT REJECTION, BRONCHIOLITIS OBLITERANS SYNDROME AND GRAFT VERSUS HOST DISEASE
    Publication number: 20220354833
    Abstract: The invention relates to treatments for organ rejection, in particular to treatments for lung transplant associated bronchiolitis obliterans syndrome by administering a neutrophil elastase inhibitor, such as alvelestat. The invention also relates to treatments for graft versus host disease.
    Type: Application
    Filed: September 17, 2020
    Publication date: November 10, 2022
    Applicants: MEREO BIOPHARMA 4 LIMITED, DUKE UNIVERSITY, NATIONAL CANCER INSTITUTE
    Inventors: Jacqueline PARKIN, Anthony SUNG, Steven Z. PAVLETIC, Annie IM, Noa G. HOLTZMAN, Cody J. PEER